Literature DB >> 19471854

Reducing the burden of influenza-associated complications with antiviral therapy.

B R Ruf1, T Szucs.   

Abstract

INTRODUCTION: Influenza imposes an annual burden on individuals, society, and healthcare systems. This burden is increased by the development of complications that are often more severe than the primary infection. Here, we examine the main complications associated with influenza and review the effectiveness of antiviral therapy in reducing the incidence of such events.
MATERIAL AND METHODS: The content of this review is taken from the study of the authors' extensive collection of reference materials, examination of the bibliographical content of relevant papers, and the results of Medline searches.
RESULTS: The most commonly encountered complications in adults are sinusitis, pharyngitis, bronchitis, and, particularly in the elderly, bacterial pneumonia. Such complications may exacerbate pulmonary complaints. Children are particularly prone to post-influenza croup and otitis media. Complications involving the central nervous system, heart, or skeletal muscle also occur in influenza patients. Influenza-associated complications impose sizeable healthcare costs in terms of outpatient contacts, hospitalizations, and antibiotic use. Vaccination is the primary prevention strategy for influenza and its complications, but has limitations. Neuraminidase inhibitors have demonstrated efficacy in reducing the incidence of influenza-associated complications in populations with different ages and risks.
CONCLUSIONS: Influenza complications place a large burden on healthcare providers and society. Neuraminidase inhibitors can reduce the incidence of such complications, particularly in high-risk groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19471854     DOI: 10.1007/s15010-009-8241-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  90 in total

1.  The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality.

Authors:  Verena H Menec; Charlyn Black; Leonard MacWilliam; Fred Y Aoki
Journal:  Can J Public Health       Date:  2003 Jan-Feb

2.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

3.  Influenza and the rates of hospitalization for respiratory disease among infants and young children.

Authors:  H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

4.  The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy.

Authors:  A Sessa; B Costa; F Bamfi; G Bettoncelli; G D'Ambrosio
Journal:  Fam Pract       Date:  2001-12       Impact factor: 2.267

5.  Rhinovirus and influenza type A infections as precipitants of asthma.

Authors:  T E Minor; E C Dick; J W Baker; J J Ouellette; M Cohen; C E Reed
Journal:  Am Rev Respir Dis       Date:  1976-02

6.  Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-04-13       Impact factor: 17.586

7.  Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.

Authors:  Jonathan A McCullers
Journal:  J Infect Dis       Date:  2004-06-30       Impact factor: 5.226

8.  What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice.

Authors:  A M Connolly; R L Salmon; B Lervy; D H Williams
Journal:  BMJ       Date:  1993-05-29

9.  Influenza-associated acute encephalopathy in Japanese children in 1994-2002.

Authors:  Takehiro Togashi; Yoshihiro Matsuzono; Mitsuo Narita; Tsuneo Morishima
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

10.  The incidence of respiratory tract infection in adults requiring hospitalization for asthma.

Authors:  H Teichtahl; N Buckmaster; E Pertnikovs
Journal:  Chest       Date:  1997-09       Impact factor: 9.410

View more
  20 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Influenza moves to the front of public health concerns.

Authors:  C Ruef
Journal:  Infection       Date:  2009-06       Impact factor: 3.553

3.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

4.  Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection.

Authors:  Kevin B O'Brien; Stacey Schultz-Cherry; Laura J Knoll
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Lymphocyte to monocyte ratio as a screening tool for influenza.

Authors:  George Merekoulias; Evangelos C Alexopoulos; Theodore Belezos; Eugenia Panagiotopoulou; Dr Med Eleni Jelastopulu
Journal:  PLoS Curr       Date:  2010-03-29

Review 6.  Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Authors:  Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

Review 7.  Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.

Authors:  Koenraad F van der Sluijs; Tom van der Poll; René Lutter; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

8.  Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice.

Authors:  Cristiana C Garcia; Remo C Russo; Rodrigo Guabiraba; Caio T Fagundes; Rafael B Polidoro; Luciana P Tavares; Ana Paula C Salgado; Geovanni D Cassali; Lirlândia P Sousa; Alexandre V Machado; Mauro M Teixeira
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

9.  A cross-sectional survey to evaluate knowledge, attitudes and practices (KAP) regarding seasonal influenza vaccination among European travellers to resource-limited destinations.

Authors:  Alena Pfeil; Margot Mütsch; Christoph Hatz; Thomas D Szucs
Journal:  BMC Public Health       Date:  2010-07-07       Impact factor: 3.295

10.  The novel influenza A (H1N1) virus pandemic: An update.

Authors:  N Petrosillo; S Di Bella; C M Drapeau; E Grilli
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.